These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 17956708

  • 21. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
    Roulin D, Demartines N, Dormond O.
    Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
    [Abstract] [Full Text] [Related]

  • 22. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M, Douis H, Porfiri E.
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
    [No Abstract] [Full Text] [Related]

  • 23. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B.
    J Clin Oncol; 2010 May 01; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract] [Full Text] [Related]

  • 24. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
    Stenner-Liewen F, Grünwald V, Greil R, Porta C.
    Expert Rev Anticancer Ther; 2013 Sep 01; 13(9):1021-33. PubMed ID: 24024788
    [Abstract] [Full Text] [Related]

  • 25. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
    Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M.
    Clin Genitourin Cancer; 2007 Sep 01; 5(6):379-85. PubMed ID: 17956710
    [Abstract] [Full Text] [Related]

  • 26. Renal cell cancer: the unmet needs.
    Durán I.
    Anticancer Drugs; 2011 Jan 01; 22 Suppl 1():S1-3. PubMed ID: 21173602
    [No Abstract] [Full Text] [Related]

  • 27. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.
    Cancer; 2011 Sep 15; 117(18):4194-200. PubMed ID: 21387258
    [Abstract] [Full Text] [Related]

  • 28. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug 15; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 29. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.
    Furge KA, MacKeigan JP, Teh BT.
    Lancet Oncol; 2010 Jun 15; 11(6):571-8. PubMed ID: 20381423
    [Abstract] [Full Text] [Related]

  • 30. Sequencing therapy in metastatic renal cell cancer.
    Escudier B, Gore M.
    Semin Oncol; 2013 Aug 15; 40(4):465-71. PubMed ID: 23972710
    [Abstract] [Full Text] [Related]

  • 31. Combination therapy in metastatic renal cell cancer.
    Ravaud A, Gross-Goupil M, Bellmunt J.
    Semin Oncol; 2013 Aug 15; 40(4):472-81. PubMed ID: 23972711
    [Abstract] [Full Text] [Related]

  • 32. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A, Fouchard N, Méry-Bossard L, Dauendorffer JN.
    Dermatology; 2011 Aug 15; 223(1):4-8. PubMed ID: 21846963
    [Abstract] [Full Text] [Related]

  • 33. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.
    Daste A, Gross-Goupil M, Roca S, Bernhard JC, Ravaud A.
    Target Oncol; 2014 Mar 15; 9(1):81-4. PubMed ID: 23283668
    [Abstract] [Full Text] [Related]

  • 34. Management of mTOR inhibitor side effects.
    Creel PA.
    Clin J Oncol Nurs; 2009 Dec 15; 13 Suppl():19-23. PubMed ID: 19948456
    [Abstract] [Full Text] [Related]

  • 35. Renal cell cancer.
    Hutson TE, Figlin RA.
    Cancer J; 2007 Dec 15; 13(5):282-6. PubMed ID: 17921725
    [Abstract] [Full Text] [Related]

  • 36. Update on the use of mTOR inhibitors in renal cell carcinoma.
    Rini BI.
    Clin Adv Hematol Oncol; 2008 Oct 15; 6(10):722-4. PubMed ID: 18997660
    [No Abstract] [Full Text] [Related]

  • 37. Temsirolimus in the treatment of advanced renal cell carcinoma.
    Gore ME.
    Ann Oncol; 2007 Jul 15; 18 Suppl 9():ix87-8. PubMed ID: 17631601
    [No Abstract] [Full Text] [Related]

  • 38. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor.
    Rothermundt C, Gillessen S.
    J Clin Oncol; 2013 Feb 10; 31(5):e57-8. PubMed ID: 23295800
    [No Abstract] [Full Text] [Related]

  • 39. Everolimus.
    Atkins MB, Yasothan U, Kirkpatrick P.
    Nat Rev Drug Discov; 2009 Jul 10; 8(7):535-6. PubMed ID: 19568281
    [No Abstract] [Full Text] [Related]

  • 40. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.
    Piha-Paul SA, Cohen PR, Kurzrock R.
    J Clin Oncol; 2011 Sep 10; 29(26):e727-30. PubMed ID: 21844496
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.